SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Flannery O'Connor

PatientFlannery O'Connor
Date of birth2001-03-25
IdentifiersMRN HR-ML046-SYN; SSN (made up) 000-46-1853
Document date2026-10-26
AuthorAugusta Pemberton-Diallo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month review of lupus nephritis; pregnancy planning. [S]

History of Present Illness

Ms. O'Connor is six months into treatment. She reached prednisone 5 mg a day a week ago. Her joints and skin remain quiet; she has had no fevers, infections, or hip pain since the summer. Monthly blood counts have been normal. She had her influenza vaccine at the preventive visit three weeks ago. She has finished a draft of her novel. She would like to have children in a few years and asked what that would mean for her treatment. [S]

ElementDetail
Interval changePrednisone 5 mg a day; no flares or infections
MedicinesMycophenolate 2 g a day; belimumab weekly; hydroxychloroquine 300 mg; losartan 25 mg; vitamin D3
QuestionPregnancy in a few years
WorkDraft of her novel finished

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight falling
MusculoskeletalNegativeNo joint pain; no hip, groin, or knee pain
IntegumentaryNegativeNo rash; hair regrowing
GenitourinaryNegativeNo urinary symptoms
PsychiatricNegativeMood good; PHQ-9 3

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a dayTwo tablets up to every 8 hours as neededOral route2026-04-13activeS
Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long termOne tablet once dailyOral route2026-04-22activeS
Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressureOne tablet once dailyOral route2026-04-22activeS
Methylprednisolone 500 mg intravenous infusion once daily for three daysOne infusion daily for three daysIntravenous route2026-04-29 to 2026-05-01completedS
Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six monthsOnce daily, taperingOral route2026-04-29activeS
Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice dailyTwo tablets twice dailyOral route2026-04-29activeS
Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weeklyOnce weekly by self-injectionSubcutaneous route2026-04-29activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-04-29activeS
Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven daysOne capsule twice daily for seven daysOral route2026-06-15 to 2026-06-21completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-26Body height168cmS
2026-10-26Body weight62kgS
2026-10-26Body mass index (BMI) [Ratio]22kg/m2S
2026-10-26Systolic blood pressure118mm[Hg]S
2026-10-26Diastolic blood pressure76mm[Hg]S
2026-10-26Heart rate72/minS
2026-10-26Respiratory rate14/minS
2026-10-26Body temperature36.6CelS
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-26Hemoglobin [Mass/volume] in Blood12.8g/dL12-15.5 g/dLNormalS
2026-10-26Leukocytes [#/volume] in Blood by Automated count5.610*3/uL4-11 10*3/uLNormalS
2026-10-26Lymphocytes [#/volume] in Blood by Automated count1.210*3/uL1-4.8 10*3/uLNormalS
2026-10-26Platelets [#/volume] in Blood by Automated count23610*3/uL150-400 10*3/uLNormalS
2026-10-26Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
2026-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-26Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-10-26Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-10-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L<=33 U/LNormalS
2026-10-26Protein/Creatinine [Mass Ratio] in Urine0.35g/g<=0.2 g/gHighS
2026-10-26Erythrocytes [#/area] in Urine sediment by Microscopy high power field2/[HPF]<=2 /[HPF]NormalS
2026-10-26DNA double strand Ab [Units/volume] in Serum38[IU]/mL<=29 [IU]/mLHighS
2026-10-26Complement C3 [Mass/volume] in Serum or Plasma96mg/dL90-180 mg/dLNormalS
2026-10-26Complement C4 [Mass/volume] in Serum or Plasma18mg/dL10-40 mg/dLNormalS
2026-10-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-10-26Pain severity - 0-10 verbal numeric rating [Score] - Reported0{score}S

Physical Exam

Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell
SkinNo rash; no mouth ulcers
MusculoskeletalNo synovitis; full, painless hip movement
CardiovascularNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be establishedresolvedconfirmed M25.50S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D).
Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be establishedresolvedconfirmed R80.9S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit.
Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negativeactiveconfirmed M32.19S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used.
Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney functionactiveconfirmed M32.14S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used.
Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or lessactiveconfirmed Z79.52S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low.
Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in placeactiveconfirmed Z79.624S — Synthetic treatment status.
Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatmentactiveconfirmed Z97.5S — Synthetic contraception, chosen by the patient.
Acute cystitis on mycophenolate, belimumab, and prednisone 15 mg: two days of burning, frequency, and urgency without fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved with seven days of nitrofurantoinresolvedconfirmed N30.00S — Synthetic common infection in an immunosuppressed young woman; coded without hematuria because the persistent hematuria is from her nephritis.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryUrine protein-to-creatinine ratio and urine sedimentEvery 3 months during active treatmentCompleted today0.35 g/g; 2 red cells per high-power field: complete renal response
LaboratoryCreatinine, eGFR, albumin, and potassiumEvery 3 months during active treatmentCompleted todayCreatinine 0.8, eGFR 101, albumin 4.1, potassium 4.3
LaboratoryAnti-dsDNA, C3, and C4Every 3 months during active treatmentCompleted todayAnti-dsDNA 38; C3 96; C4 18
LaboratoryBlood count and liver tests on mycophenolateMonthly in the first yearCompleted todayWhite cells 5.6, lymphocytes 1.2, hemoglobin 12.8, platelets 236; ALT 20
ExaminationBlood pressureEvery visitCompleted today118/76 mmHg
Medication safetyGlucocorticoid doseEvery visitCompleted todayPrednisone 5 mg a day at six months, as planned
ExaminationAvascular necrosis symptomsEvery visitCompleted todayNo hip, groin, or knee pain
ImagingBone density (DXA)Every 1 to 3 years on glucocorticoidsUp to dateNormal six months ago
Medication safetyHydroxychloroquine eye screeningYearly from five years of useUp to dateBaseline normal four months ago
Medication safetyVaccinationsYearly influenza; others as dueUp to dateInfluenza three weeks ago; PCV20 and two zoster doses done; COVID-19 booked
Medication safetyContraception and pregnancy planningEvery visitCompleted todayIntrauterine system in place; pregnancy plan discussed
LaboratoryAnti-Ro and anti-La antibodiesBefore pregnancyDueWhen she plans a pregnancy
LaboratoryLipidsYearly on glucocorticoidsDueAt one year
SurveyMood on belimumab (PHQ-9)PeriodicallyCompleted todayPHQ-9 3
SurveyJoint pain scoreEvery visitCompleted today0 of 10
Self-managementSun protection and writing scheduleEvery visitCompleted todaySunscreen daily; draft of her novel finished

Goal progress:

Guideline basis: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024); 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res 2020;72(4):461-488 (2020); CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease and hypertension monographs (2026)

Follow-up: Rheumatology every three months with kidney panel, urine protein, and serology. Blood counts monthly to one year. Primary care review in three months. [S]